RemeGen Co., Ltd.

OTCPK:REGM.F Stock Report

Market Cap: US$8.5b

RemeGen Valuation

Is REGM.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of REGM.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: REGM.F ($10) is trading below our estimate of future cash flow value ($14.06)

Significantly Below Future Cash Flow Value: REGM.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGM.F?

Key metric: As REGM.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for REGM.F. This is calculated by dividing REGM.F's market cap by their current earnings.
What is REGM.F's PE Ratio?
PE Ratio62.4x
EarningsCN¥708.52m
Market CapCN¥58.24b

Price to Earnings Ratio vs Peers

How does REGM.F's PE Ratio compare to its peers?

The above table shows the PE ratio for REGM.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.6x
HALO Halozyme Therapeutics
24.8x12.01%US$8.0b
ARWR Arrowhead Pharmaceuticals
40.2x3.07%US$8.3b
PTCT PTC Therapeutics
8x-8.39%US$5.7b
ADMA ADMA Biologics
25.4x23.17%US$3.8b
REGM.F RemeGen
62.4x23.84%US$66.4b

Price-To-Earnings vs Peers: REGM.F is expensive based on its Price-To-Earnings Ratio (62.4x) compared to the peer average (25.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does REGM.F's PE Ratio compare vs other companies in the US Biotechs Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NVAX Novavax
4x-34.86%US$1.74b
RIGL Rigel Pharmaceuticals
1.4x-33.20%US$525.38m
ABEO Abeona Therapeutics
3.3x19.52%US$278.54m
KROS Keros Therapeutics
2.6x-29.15%US$228.33m
REGM.F 62.4xIndustry Avg. 21.5xNo. of Companies11PE01632486480+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: REGM.F is expensive based on its Price-To-Earnings Ratio (62.4x) compared to the US Biotechs industry average (21.5x).

Price to Earnings Ratio vs Fair Ratio

What is REGM.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGM.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate REGM.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REGM.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$12.57
0%
29.77%US$18.53US$3.85n/a15
Mar ’27n/a
US$12.36
0%
32.89%US$18.60US$3.86n/a15
Feb ’27n/a
US$11.63
0%
38.12%US$18.39US$3.82n/a15
Jan ’27US$9.81
US$10.29
+4.90%
38.74%US$18.46US$3.79n/a15
Dec ’26n/a
US$10.22
0%
38.69%US$18.29US$3.75n/a15
Nov ’26US$11.00
US$9.51
-13.51%
42.18%US$18.16US$3.73n/a15
Oct ’26n/a
US$9.46
0%
41.67%US$17.66US$3.73n/a15
Sep ’26n/a
US$8.53
0%
47.07%US$15.06US$2.05n/a15
Aug ’26n/a
US$5.53
0%
30.80%US$8.50US$2.02n/a14
Jul ’26n/a
US$5.08
0%
37.93%US$8.56US$2.08n/a15
Jun ’26n/a
US$4.41
0%
31.73%US$6.54US$2.07n/a15
May ’26US$5.06
US$3.83
-24.40%
34.54%US$6.45US$2.05n/a15
Apr ’26n/a
US$3.21
0%
27.39%US$4.88US$2.05n/a15
Mar ’26n/a
US$3.20
0%
34.40%US$6.36US$2.05n/a15
Feb ’26n/a
US$3.22
0%
34.41%US$6.39US$2.05n/a15
Jan ’26n/a
US$3.22
0%
33.75%US$6.36US$2.04US$9.8115
Dec ’25n/a
US$3.21
0%
31.81%US$6.25US$2.05n/a16
Nov ’25n/a
US$3.29
0%
32.48%US$6.36US$2.06US$11.0015
Oct ’25n/a
US$3.24
0%
36.59%US$6.44US$1.98n/a14
Sep ’25n/a
US$3.20
0%
36.51%US$6.36US$1.95n/a14
Aug ’25n/a
US$4.85
0%
30.10%US$8.07US$2.69n/a14
Jul ’25n/a
US$5.11
0%
25.17%US$8.06US$3.57n/a13
Jun ’25n/a
US$5.36
0%
26.87%US$8.07US$3.58n/a14
May ’25n/a
US$5.48
0%
25.75%US$8.05US$3.57US$5.0613
Apr ’25n/a
US$5.72
0%
29.07%US$8.05US$3.31n/a12
Mar ’25n/a
US$6.81
0%
24.87%US$8.48US$3.32n/a13
US$10.86
Fair Value
7.9% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/11 06:40
End of Day Share Price 2026/03/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RemeGen Co., Ltd. is covered by 30 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shun Kei LawCCB International Securities Limited
Zhishun SiuCCB International Securities Limited
Ziyu HeChina International Capital Corporation Limited